clotrimazole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
719 23593-75-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clotrimazole
  • lotrimin
  • rimazole
  • locasten
An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.
  • Molecular weight: 344.84
  • Formula: C22H17ClN2
  • CLOGP: 5
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 17.82
  • ALOGS: -5.37
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g V

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.03 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.07 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 3, 1975 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 847.15 14.16 292 15548 24084 63449098
Schizoaffective disorder 430.97 14.16 112 15728 3450 63469732
Drug level increased 249.26 14.16 119 15721 22617 63450565
Chronic sinusitis 177.58 14.16 79 15761 12764 63460418
Electrocardiogram QT prolonged 158.65 14.16 126 15714 59404 63413778
Paraesthesia oral 158.49 14.16 83 15757 19173 63454009
Procedural pain 141.49 14.16 80 15760 21489 63451693
Oral candidiasis 109.02 14.16 69 15771 22729 63450453
Vaginal flatulence 93.44 14.16 34 15806 3259 63469923
Dyspepsia 82.48 14.16 114 15726 102082 63371100
Proctitis 76.90 14.16 34 15806 5407 63467775
Vaginal discharge 68.20 14.16 37 15803 9161 63464021
Female genital tract fistula 66.25 14.16 34 15806 7525 63465657
Radiculopathy 62.08 14.16 34 15806 8577 63464605
Endocrine ophthalmopathy 61.73 14.16 17 15823 654 63472528
Vulvovaginal candidiasis 58.68 14.16 24 15816 3151 63470031
Toxic shock syndrome 57.91 14.16 17 15823 825 63472357
Swelling of eyelid 52.06 14.16 22 15818 3134 63470048
Drug interaction 50.21 14.16 148 15692 228983 63244199
Sinus rhythm 49.00 14.16 15 15825 841 63472341
Eyelid disorder 44.79 14.16 17 15823 1832 63471350
Nasal ulcer 44.58 14.16 18 15822 2286 63470896
Rectal haemorrhage 41.48 14.16 56 15784 48974 63424208
Mean cell haemoglobin increased 40.33 14.16 18 15822 2925 63470257
Eye infection toxoplasmal 39.19 14.16 10 15830 285 63472897
Vanishing bile duct syndrome 38.41 14.16 12 15828 720 63472462
Frequent bowel movements 37.70 14.16 37 15803 22985 63450197
Haematochezia 36.25 14.16 55 15785 53489 63419693
Swollen tongue 32.93 14.16 42 15798 34758 63438424
Dyslipidaemia 31.94 14.16 21 15819 7372 63465810
Therapeutic product effect decreased 31.93 14.16 5 15835 193182 63280000
Drug ineffective 31.71 14.16 398 15442 1044367 62428815
Weight decreased 31.06 14.16 144 15696 276654 63196528
Glossodynia 31.03 14.16 4 15836 178872 63294310
Pelvic pain 30.49 14.16 26 15814 13493 63459689
Therapeutic product effect incomplete 30.48 14.16 84 15756 124972 63348210
Colitis ulcerative 30.41 14.16 35 15805 26056 63447126
Candida infection 29.68 14.16 36 15804 28315 63444867
Purpura senile 28.58 14.16 9 15831 554 63472628
Rheumatoid arthritis 26.80 14.16 15 15825 253804 63219378
Tongue blistering 25.91 14.16 11 15829 1584 63471598
Drug intolerance 25.12 14.16 24 15816 308637 63164545
Vulvovaginal inflammation 25.06 14.16 9 15831 830 63472352
Malaise 24.78 14.16 183 15657 415771 63057411
Tarsal tunnel syndrome 24.33 14.16 8 15832 566 63472616
Toxicity to various agents 24.16 14.16 16 15824 247234 63225948
Colitis 23.64 14.16 43 15797 48485 63424697
Synovial cyst 23.39 14.16 20 15820 10413 63462769
Feeding disorder 22.86 14.16 22 15818 13340 63459842
Hepatic enzyme increased 22.77 14.16 11 15829 202317 63270865
Eye infection 22.70 14.16 21 15819 12124 63461058
Angiodermatitis 22.58 14.16 5 15835 76 63473106
Wound complication 22.16 14.16 13 15827 3734 63469448
Erythema 20.85 14.16 93 15747 175658 63297524
Febrile neutropenia 20.84 14.16 71 15769 118378 63354804
Skin laceration 20.84 14.16 27 15813 22681 63450501
Post viral fatigue syndrome 20.05 14.16 6 15834 311 63472871
Abdominal discomfort 19.72 14.16 31 15809 320854 63152328
Vitamin D decreased 19.70 14.16 18 15822 10224 63462958
Discomfort 18.98 14.16 9 15831 167365 63305817
Aplastic anaemia 18.77 14.16 17 15823 9552 63463630
Alopecia 18.56 14.16 35 15805 337501 63135681
Wound 18.18 14.16 9 15831 163254 63309928
Resorption bone increased 18.13 14.16 8 15832 1266 63471916
Pyrexia 18.09 14.16 188 15652 470290 63002892
Neutropenic sepsis 17.41 14.16 21 15819 16417 63456765
Vestibular disorder 17.23 14.16 8 15832 1423 63471759
Reperfusion arrhythmia 17.10 14.16 5 15835 239 63472943
Vulvovaginal discomfort 16.07 14.16 9 15831 2369 63470813
Mouth ulceration 15.77 14.16 29 15811 32955 63440227
Congenital absence of bile ducts 14.89 14.16 3 15837 28 63473154
Nausea 14.89 14.16 297 15543 854174 62619008
General physical health deterioration 14.86 14.16 17 15823 201385 63271797
Stevens-Johnson syndrome 14.62 14.16 24 15816 24926 63448256
Musculoskeletal stiffness 14.26 14.16 15 15825 184603 63288579

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary vasculitis 43.95 15.10 12 6670 587 34949662
Neuritis 38.68 15.10 12 6670 922 34949327
Respiratory symptom 31.00 15.10 12 6670 1785 34948464
Neurological symptom 26.89 15.10 14 6668 4171 34946078
Temperature regulation disorder 24.20 15.10 8 6674 754 34949495
Skin infection 21.24 15.10 15 6667 7722 34942527
Cellulitis 21.14 15.10 37 6645 52914 34897335
Hypoglycaemia neonatal 20.26 15.10 9 6673 1892 34948357
Lip haemorrhage 20.19 15.10 7 6675 763 34949486
Accident 19.22 15.10 12 6670 5035 34945214
Sleep disorder due to a general medical condition 18.85 15.10 12 6670 5209 34945040
Dermatitis atopic 18.59 15.10 12 6670 5335 34944914
Aplastic anaemia 18.21 15.10 15 6667 9701 34940548
Rash pruritic 18.12 15.10 24 6658 26917 34923332
Microtia 17.65 15.10 5 6677 280 34949969
Congenital umbilical hernia 17.33 15.10 5 6677 299 34949950
Dermatitis 16.46 15.10 14 6668 9454 34940795
Vasculitis 16.25 15.10 15 6667 11281 34938968

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 180.17 13.23 75 18209 11221 79714883
Chronic sinusitis 173.11 13.23 76 18208 12950 79713154
Paraesthesia oral 151.71 13.23 80 18204 20391 79705713
Procedural pain 137.29 13.23 78 18206 23006 79703098
Oral candidiasis 102.53 13.23 71 18213 29557 79696547
Vaginal flatulence 100.39 13.23 33 18251 2542 79723562
Dyspepsia 82.96 13.23 113 18171 108574 79617530
Vaginal discharge 75.41 13.23 36 18248 7427 79718677
Female genital tract fistula 73.39 13.23 33 18251 5942 79720162
Proctitis 71.07 13.23 33 18251 6399 79719705
Vulvovaginal candidiasis 66.09 13.23 24 18260 2490 79723614
Radiculopathy 63.99 13.23 34 18250 8790 79717314
Endocrine ophthalmopathy 61.77 13.23 17 18267 711 79725393
Toxic shock syndrome 56.83 13.23 18 18266 1231 79724873
Swelling of eyelid 53.11 13.23 23 18261 3788 79722316
Nasal ulcer 47.34 13.23 18 18266 2122 79723982
Eyelid disorder 45.07 13.23 17 18267 1961 79724143
Therapeutic product effect incomplete 42.83 13.23 98 18186 141547 79584557
Haematochezia 40.05 13.23 72 18212 87573 79638531
Pulmonary vasculitis 38.95 13.23 12 18272 749 79725355
Toxicity to various agents 37.99 13.23 25 18259 421515 79304589
Aplastic anaemia 37.84 13.23 32 18252 17873 79708231
Pelvic pain 37.00 13.23 28 18256 13353 79712751
Frequent bowel movements 36.08 13.23 39 18245 29500 79696604
Mean cell haemoglobin increased 35.34 13.23 18 18266 4267 79721837
Swollen tongue 35.11 13.23 46 18238 42524 79683580
Eye infection toxoplasmal 33.83 13.23 10 18274 542 79725562
Dyslipidaemia 31.41 13.23 24 18260 11609 79714495
Rectal haemorrhage 30.27 13.23 59 18225 76241 79649863
Wound complication 30.02 13.23 17 18267 4976 79721128
Neuritis 29.13 13.23 12 18272 1746 79724358
Vanishing bile duct syndrome 29.00 13.23 12 18272 1766 79724338
Candida infection 28.02 13.23 39 18245 38175 79687929
Colitis ulcerative 27.81 13.23 37 18247 34705 79691399
Tongue blistering 27.05 13.23 11 18273 1548 79724556
Therapeutic product effect decreased 27.02 13.23 3 18281 163860 79562244
Overdose 26.60 13.23 5 18279 184201 79541903
Weight decreased 26.34 13.23 155 18129 355043 79371061
Purpura senile 25.62 13.23 8 18276 522 79725582
Rash pruritic 25.55 13.23 53 18231 71576 79654528
Tarsal tunnel syndrome 25.53 13.23 8 18276 528 79725576
Synovial cyst 25.51 13.23 20 18264 10045 79716059
Eye infection 24.56 13.23 21 18263 11899 79714205
Angiodermatitis 23.12 13.23 5 18279 74 79726030
Vitamin D decreased 21.83 13.23 18 18266 9707 79716397
Rheumatoid arthritis 20.68 13.23 11 18273 208459 79517645
Stevens-Johnson syndrome 20.26 13.23 34 18250 39132 79686972
Post viral fatigue syndrome 19.98 13.23 6 18278 343 79725761
Malaise 19.28 13.23 184 18100 489685 79236419
Feeding disorder 19.04 13.23 21 18263 16233 79709871
Gingival swelling 18.22 13.23 12 18272 4597 79721507
Systemic lupus erythematosus 18.12 13.23 3 18281 121146 79604958
Psoriasis 17.81 13.23 53 18231 89534 79636570
Respiratory symptom 17.79 13.23 12 18272 4779 79721325
Resorption bone increased 17.65 13.23 8 18276 1467 79724637
Vasculitis 17.48 13.23 25 18259 25077 79701027
Nausea 17.47 13.23 312 17972 956884 78769220
Pruritus 17.43 13.23 152 18132 394496 79331608
Vulvovaginal inflammation 17.34 13.23 6 18278 540 79725564
Urinary tract infection 17.33 13.23 115 18169 274397 79451707
Febrile neutropenia 17.22 13.23 101 18183 230898 79495206
Genital rash 16.98 13.23 7 18277 1021 79725083
Flatulence 16.89 13.23 33 18251 42691 79683413
Headache 16.85 13.23 226 18058 653546 79072558
Reperfusion arrhythmia 16.50 13.23 5 18279 295 79725809
Erythema 16.24 13.23 97 18187 223193 79502911
Pyrexia 16.02 13.23 231 18053 678478 79047626
Vulvovaginal discomfort 15.97 13.23 8 18276 1830 79724274
Lip haemorrhage 15.97 13.23 7 18277 1187 79724917
Mouth ulceration 15.60 13.23 30 18254 38364 79687740
Neurological symptom 15.16 13.23 14 18270 8769 79717335
Plicated tongue 15.06 13.23 4 18280 146 79725958
Urosepsis 15.06 13.23 24 18260 26471 79699633
Swelling face 14.99 13.23 43 18241 71169 79654935
Oral mucosal blistering 14.94 13.23 12 18272 6239 79719865
Musculoskeletal stiffness 14.91 13.23 11 18273 174997 79551107
Vulvovaginal pain 14.57 13.23 8 18276 2207 79723897
Skin disorder 14.38 13.23 27 18257 33916 79692188
Pain 14.10 13.23 233 18051 703569 79022535
Coma 13.97 13.23 3 18281 100646 79625458
Arthrodesis 13.94 13.23 8 18276 2399 79723705
Vestibular disorder 13.80 13.23 8 18276 2447 79723657
Skin ulcer 13.70 13.23 35 18249 54115 79671989
Skin laceration 13.49 13.23 24 18260 28938 79697166
Neutropenic sepsis 13.35 13.23 23 18261 27041 79699063
Kidney transplant rejection 13.34 13.23 14 18270 10232 79715872
Colitis 13.29 13.23 42 18242 73265 79652839
Hypercholesterolaemia 13.23 13.23 21 18263 23074 79703030

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AB18 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Antiinfectives and antiseptics for local oral treatment
ATC D01AC01 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Imidazole and triazole derivatives
ATC G01AF02 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Imidazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000891 Anti-Infective Agents, Local
MeSH PA D000935 Antifungal Agents
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Candidiasis of skin indication 49883006
Pityriasis versicolor indication 56454009 DOID:9060
Candidal vulvovaginitis indication 72605008 DOID:2272
Candidiasis of mouth indication 79740000 DOID:14262
Tinea corporis indication 84849002
Diaper rash indication 91487003
Tinea cruris indication 399029005
Prevention of Oropharyngeal Candidiasis indication
Oropharyngeal Candidiasis indication
Paronychia off-label use 71906005 DOID:13117
Telangiectasia disorder contraindication 247479008
Abdominal pain - cause unknown contraindication 314212008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Fungal infections caused by Microsporum canis Indication
Cats Fungal infections caused by Trichophyton mentagrophytes Indication
Cats Otitis externa caused by yeast, Malassezia pachydermatis Indication
Dogs Fungal infections caused by Microsporum canis Indication
Dogs Fungal infections caused by Trichophyton mentagrophytes Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Veltrim 1% Dermatologic Cream Elanco US Inc. 1
Otomax Intervet Inc. 3
Mometamax Otic Suspension Intervet Inc. 3
Tri-Otic Ointment Med-Pharmex Inc. 3
Vetro-Max Fougera Pharmaceuticals Inc. 3
GBC Ointment Cronus Pharma Specialities India Private Limited 3
Mometavet Med-Pharmex Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.4 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR Ki 5.19 DRUG MATRIX
Prostaglandin G/H synthase 2 Enzyme IC50 4.38 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor ANTAGONIST IC50 6.16 IUPHAR
Mu-type opioid receptor GPCR Ki 6.14 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.35 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.39 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.15 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.35 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.52 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 7.70 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.51 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.10 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.00 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.50 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.13 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.12 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.24 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.43 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.05 DRUG MATRIX
Histamine H1 receptor GPCR Ki 5.47 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.29 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 5.78 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.29 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 5.68 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 5.79 DRUG MATRIX
Glucocorticoid receptor Nuclear hormone receptor Ki 5.83 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 5.27 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.35 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 5.11 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.57 DRUG MATRIX
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel IC50 7.15 CHEMBL
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
D(4) dopamine receptor GPCR Ki 5.16 DRUG MATRIX
Carbonic anhydrase 2 Enzyme IC50 4.52 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.13 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.60 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.76 DRUG MATRIX
Acetylcholinesterase Enzyme IC50 4.71 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 7.80 DRUG MATRIX
Platelet-activating factor receptor GPCR Ki 4.65 DRUG MATRIX
Aromatase Enzyme IC50 8.74 CHEMBL
Cysteinyl leukotriene receptor 1 GPCR Ki 4.78 CHEMBL
Epidermal growth factor receptor Kinase IC50 4.16 DRUG MATRIX
Vasopressin V2 receptor GPCR IC50 5.60 CHEMBL
Substance-P receptor GPCR Ki 5.06 DRUG MATRIX
Steroid 17-alpha-hydroxylase/17,20 lyase Enzyme IC50 7.09 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 3 Ion channel IC50 5.22 CHEMBL
Cytochrome P450 2C19 Enzyme IC50 7.80 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 4.50 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 4.18 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 7.85 DRUG MATRIX
Bile acid receptor Nuclear hormone receptor IC50 5.49 CHEMBL
Lanosterol 14-alpha demethylase Enzyme IC50 6.89 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.92 CHEMBL
Substance-K receptor GPCR Ki 5.47 DRUG MATRIX
Transient receptor potential cation channel subfamily M member 2 Ion channel IC50 5.52 CHEMBL
C-C chemokine receptor type 4 GPCR IC50 5.80 CHEMBL
C-X-C chemokine receptor type 1 GPCR IC50 5.70 CHEMBL
Transitional endoplasmic reticulum ATPase Enzyme IC50 5.85 CHEMBL
Malate dehydrogenase cytoplasmic Enzyme IC50 4.46 CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 6.10 CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.17 WOMBAT-PK
Lanosterol 14-alpha demethylase Enzyme INHIBITOR CHEMBL CHEMBL
Beta-lactamase Enzyme IC50 4.70 CHEMBL
Androgen receptor Transcription factor Ki 5.11 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 4.91 DRUG MATRIX
Cysteinyl leukotriene receptor 1 GPCR Ki 4.78 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.94 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 4.58 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 4.75 CHEMBL
Lanosterol 14-alpha demethylase Enzyme Kd 6.70 CHEMBL
14-alpha sterol demethylase Cyp51A Enzyme Kd 5.32 CHEMBL
14-alpha sterol demethylase Enzyme Kd 6.99 CHEMBL
Indoleamine 2,3-dioxygenase 2 Enzyme IC50 5.23 CHEMBL
Mycocyclosin synthase Enzyme Kd 7.14 CHEMBL
Putative cytochrome P450 130 Enzyme Kd 4.88 CHEMBL
Alpha-chymotrypsin Enzyme IC50 4.07 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 4.29 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme Ki 4.46 CHEMBL

External reference:

IDSource
4018265 VUID
N0000146595 NUI
D00282 KEGG_DRUG
202859 RXNORM
4018265 VANDF
C0009074 UMLSCUI
CHEBI:3764 CHEBI
CL6 PDB_CHEM_ID
CHEMBL104 ChEMBL_ID
DB00257 DRUGBANK_ID
D003022 MESH_DESCRIPTOR_UI
2812 PUBCHEM_CID
2330 IUPHAR_LIGAND_ID
2912 INN_ID
G07GZ97H65 UNII
1284 MMSL
4482 MMSL
d01236 MMSL
002916 NDDF
387325003 SNOMEDCT_US
5797005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-4146 LOZENGE 10 mg ORAL ANDA 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-4146 LOZENGE 10 mg ORAL ANDA 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-8146 LOZENGE 10 mg ORAL ANDA 14 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-8146 LOZENGE 10 mg ORAL ANDA 14 sections
Lotrisone HUMAN PRESCRIPTION DRUG LABEL 2 0085-0924 CREAM 10 mg TOPICAL NDA 26 sections
Good Sense Athletes Footantifungal HUMAN OTC DRUG LABEL 1 0113-0857 CREAM 1 g TOPICAL OTC monograph final 13 sections
Clotrimazole HUMAN PRESCRIPTION DRUG LABEL 1 0168-0133 CREAM 10 mg TOPICAL ANDA 20 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0258 CREAM 10 mg TOPICAL ANDA 27 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0370 LOTION 10 mg TOPICAL ANDA 20 sections
Fungicure Liquid Gel HUMAN OTC DRUG LABEL 1 0295-1363 LIQUID 10 mg TOPICAL OTC monograph final 9 sections
Fungicure Manicure Pedicure Anti Fungal HUMAN OTC DRUG LABEL 1 0295-6307 LIQUID 1 mg TOPICAL OTC monograph final 10 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-0220 CREAM 10 mg VAGINAL ANDA 16 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-0220 CREAM 10 mg VAGINAL ANDA 16 sections
WALGREENS CLOTRIMAZOLE HUMAN OTC DRUG LABEL 1 0363-1299 CREAM 1 g TOPICAL OTC monograph final 11 sections
athletes foot HUMAN OTC DRUG LABEL 1 0363-1857 CREAM 1 g TOPICAL OTC monograph final 13 sections
Walgreens Clotrimazole 3 HUMAN OTC DRUG LABEL 1 0363-2062 CREAM 2 g VAGINAL NDA 16 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-2105 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Ringworm HUMAN OTC DRUG LABEL 1 0363-2107 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Ringworm HUMAN OTC DRUG LABEL 1 0363-2107 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Walgreens Jock Itch HUMAN OTC DRUG LABEL 1 0363-2109 CREAM 10 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0363-3492 LIQUID 1 mg TOPICAL OTC monograph final 8 sections
Walgreens Clotrimazole Antifungal HUMAN OTC DRUG LABEL 1 0363-7412 CREAM 1 g TOPICAL OTC monograph final 11 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0472-0220 CREAM 10 mg VAGINAL ANDA 16 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0472-0220 CREAM 10 mg VAGINAL ANDA 16 sections
ClotrimazoleAntifungal HUMAN OTC DRUG LABEL 1 0472-0350 CREAM 10 mg TOPICAL OTC monograph final 13 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0472-0379 CREAM 10 mg TOPICAL ANDA 24 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0472-0379 CREAM 10 mg TOPICAL ANDA 24 sections
Clotrimazole HUMAN OTC DRUG LABEL 1 0536-1181 SOLUTION 1 g TOPICAL OTC monograph final 13 sections
Rugby Clotrimazole Antifungal Cream HUMAN OTC DRUG LABEL 1 0536-1265 CREAM 1 g TOPICAL OTC monograph final 12 sections
Rugby Clotrimazole Antifungal Cream HUMAN OTC DRUG LABEL 1 0536-1265 CREAM 1 g TOPICAL OTC monograph final 12 sections